CMV Congenital CMV is common disease causing long-term morbidities, but is often unidentified at birth. This study assessed the cost effectiveness of universal screening compared to identification by newborn hearing test failure for congenital CMV in neonates >21 days of age. The study demonstrated that in highly resourced settings, universal screening for congenital CMV improves outcomes in neonates with congenital CMV.
VALGANCICLOVIR The long-term audiologic benefits of ganciclovir treatment for CMV infection are unclear. This randomized controlled trial evaluated the effectiveness of 6 week or 6 month valganciclovir therapy in improving audiologic outcomes. Although short-term outcomes were not different between groups, 6 month-treatment was associated with a slight improvement in hearing and neurodevelopmental outcome at 12 and 24 months. Thus, extended valganciclovir treatment may be appropriate for CMV infection.